Johnson & Johnson (NYSE:JNJ) Expected to Announce Quarterly Sales of $20.78 Billion

Analysts expect Johnson & Johnson (NYSE:JNJ) to report sales of $20.78 billion for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for Johnson & Johnson’s earnings, with the highest sales estimate coming in at $20.82 billion and the lowest estimate coming in at $20.71 billion. Johnson & Johnson posted sales of $20.39 billion during the same quarter last year, which would indicate a positive year-over-year growth rate of 1.9%. The company is expected to report its next earnings report before the market opens on Wednesday, January 22nd.

On average, analysts expect that Johnson & Johnson will report full year sales of $82.04 billion for the current fiscal year, with estimates ranging from $81.42 billion to $82.44 billion. For the next year, analysts expect that the firm will report sales of $85.47 billion, with estimates ranging from $84.71 billion to $86.39 billion. Zacks’ sales averages are an average based on a survey of research analysts that that provide coverage for Johnson & Johnson.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, October 15th. The company reported $2.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.00 by $0.12. Johnson & Johnson had a return on equity of 39.81% and a net margin of 21.09%. The business had revenue of $20.73 billion during the quarter, compared to the consensus estimate of $20.14 billion. During the same quarter last year, the firm posted $2.05 EPS. The company’s quarterly revenue was up 1.9% on a year-over-year basis.

Several equities research analysts have commented on JNJ shares. Cantor Fitzgerald initiated coverage on shares of Johnson & Johnson in a report on Wednesday, November 27th. They set an “overweight” rating and a $160.00 price objective on the stock. Morgan Stanley restated an “equal weight” rating and set a $145.00 price target on shares of Johnson & Johnson in a research note on Tuesday, August 27th. Sanford C. Bernstein upgraded shares of Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $155.00 price target on the stock in a research note on Friday, October 11th. Atlantic Securities upgraded shares of Johnson & Johnson from an “underweight” rating to a “neutral” rating in a research note on Wednesday, October 16th. Finally, Goldman Sachs Group set a $169.00 target price on Johnson & Johnson and gave the stock a “buy” rating in a research report on Tuesday, August 27th. Six equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $152.33.

NYSE JNJ traded up $0.36 during trading on Monday, hitting $141.34. 5,011,364 shares of the company’s stock traded hands, compared to its average volume of 7,136,442. The stock has a market capitalization of $369.78 billion, a price-to-earnings ratio of 17.28, a PEG ratio of 2.37 and a beta of 0.70. Johnson & Johnson has a 12-month low of $121.00 and a 12-month high of $148.59. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.00 and a current ratio of 1.26. The business has a 50 day moving average of $134.73 and a 200-day moving average of $133.65.

The company also recently declared a quarterly dividend, which was paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th were issued a $0.95 dividend. This represents a $3.80 dividend on an annualized basis and a dividend yield of 2.69%. The ex-dividend date of this dividend was Monday, November 25th. Johnson & Johnson’s payout ratio is 46.45%.

Several institutional investors have recently made changes to their positions in JNJ. Virtus ETF Advisers LLC purchased a new stake in shares of Johnson & Johnson in the 2nd quarter valued at about $25,000. Krane Funds Advisors LLC purchased a new stake in Johnson & Johnson in the second quarter valued at approximately $26,000. Financial Advantage Inc. purchased a new stake in Johnson & Johnson in the third quarter valued at approximately $28,000. Crewe Advisors LLC raised its stake in Johnson & Johnson by 725.9% in the second quarter. Crewe Advisors LLC now owns 223 shares of the company’s stock valued at $31,000 after purchasing an additional 196 shares in the last quarter. Finally, Permanens Capital L.P. raised its stake in Johnson & Johnson by 50.0% in the second quarter. Permanens Capital L.P. now owns 300 shares of the company’s stock valued at $42,000 after purchasing an additional 100 shares in the last quarter. 67.34% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Recommended Story: How Investors Use a Balance Sheet

Get a free copy of the Zacks research report on Johnson & Johnson (JNJ)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.